Bloomberg Intelligence

Metsera Tumbles After Novo Pulls Out of Bidding War With Pfizer

7 snips
Nov 10, 2025
Sam Fazeli, Director of Research for Global Industries at Bloomberg Intelligence, discusses how MetSera ended its bidding war with Pfizer after regulatory concerns from the FTC. Mandeep Singh, a senior tech analyst, reveals TSMC's slow sales growth and how Nvidia is pushing for more chip supplies amid AI demand. Jennifer Bartashus, a retail staples analyst, covers Tyson Foods' struggles due to cattle shortages affecting beef prices and hints that turkey prices might rise this Thanksgiving due to avian flu.
Ask episode
AI Snips
Chapters
Books
Transcript
Episode notes
INSIGHT

MetSera Drug Is Competitive And Once-Monthly

  • MetSera's once-monthly obesity drug appears competitive with manageable early side effects like nausea and vomiting.
  • Pfizer won the bidding after flagging FTC regulatory concerns forced Novo Nordisk to stop raising its offer.
INSIGHT

FTC Concerns Swayed The Bidding War

  • Novo Nordisk pursued MetSera to add options for its salesforce but faced competition and regulatory risk.
  • The FTC warned MetSera about potential antitrust issues with Novo's deal structure, influencing the outcome.
INSIGHT

Novo Is Expanding Options, Not Desperation

  • Novo Nordisk isn't desperate but seeks more obesity assets to compete with Lilly's market-leading drugs.
  • Multiple mechanisms and upcoming obesity assets mean the space will remain contested.
Get the Snipd Podcast app to discover more snips from this episode
Get the app